Protonentherapie Publicaties

De afgelopen jaren heeft de Universiteit Maastricht/MAASTRO clinic veel onderzoek gedaan naar protonentherapie. Dat heeft geresulteerd in een groot aantal, bijna 50!, wetenschappelijke publicaties in toonaangevende vaktijdschriften. Dit aantal zal aanmerkelijk gaan toenemen wanneer de protonentherapie ook effectief in Maastricht tot de behandelopties zal behoren.

1. Hansen D, Sorenssen TS, Seco J, Verhaegen F, Landry G. A comparison of dual energy CT and proton CT for stopping powers estimation. Acta Oncol. 2015;54:1638–42.

2. Hansen DC, Seco J, Sørensen TS, Petersen JBB, Wildberger JE, Verhaegen F, Landry G. A simulation study on proton computed tomography (CT) stopping power accuracy using dual energy CT scans as benchmark. Acta Oncol. 2015;54(9):1638–42.

3. Palmans H, Thomas R, Simon M, Duane S, Kacperek A, DuSautoy A, Verhaegen F. A small-body portable graphite calorimeter for dosimetry in low-energy clinical proton beams. Phys Med Biol. 2004 Aug 21;49(16):3737–49.

4. Palmans H, Verhaegen F. Assigning nonelastic nuclear interaction cross sections to Hounsfield units for Monte Carlo treatment planning of proton beams. Phys Med Biol. 2005 Mar 7;50(5):991–1000.

5. Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol. 2007 May;83(2):110–22.

6. Walsh S, Roelofs E, Kuess P, Lambin P, Jones B, Georg D, Verhaegen F. A validated tumor control probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy. Med Phys. 2016 Feb;43(2):734.

7. Eekers D, Roelofs E, Jelen U, Kirk M, Granzier M, Ammazzalorso F. Benefit of particle therapy in re-irradiation of head and neck patients. Results of a multicentric in silico ROCOCO trial. Radiother Oncol. 2016;

8. Palmans H, Verhaegen F. Calculated depth dose distributions for proton beams in some low-Z materials. Phys Med Biol. 1997 Jun;42(6):1175–83.

9. De Ruysscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, Pijls-Johannesma M. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol. 2012 Apr;103(1):5–7.

10. De Ruysscher D, Chang JY. Clinical controversies: proton therapy for thoracic tumors. Semin Radiat Oncol. 2013 Apr;23(2):115–9.

11. Hudobivnik N, Schwarz F, Johnson T, Agolli L, Dedes G, Tessonnier T, Verhaegen F, Thieke C, Belka C, Sommer WH, Parodi K, Landry G. Comparison of proton therapy treatment planning for head tumors with a pencil beam algorithm on dual and single energy CT images. Med Phys. 2016 Jan;43(1):495.

12. Grutters JPC, Kessels AGH, Pijls-Johannesma M, De Ruysscher D, Joore MA, Lambin P. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol. 2010 Apr;95(1):32–40.

13. Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB 2nd, Rengan R, Feigenberg S, Khan AJ. Consensus statement of proton therapy in early stage and locally advanced non–small cell lung cancer. Int J Radiat Oncol Biol Phys. 2016;

14. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: current evidence and future needs. Radiother Oncol. 2008 Nov;89(2):127–34.

15. Lambin P, Zindler J, Vanneste BGL, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RTHM, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EEC, Even AJG, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RTH, Zegers CML, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev. 2016 Jan 14;

16. Roelofs E, Persoon L, Qamhiyeh S, Verhaegen F, De Ruysscher D, Scholz M, Iancu G, Engelsman M, Rasch C, Zijp L, Meerleer GD, Coghe M, Langendijk J, Schilstra C, Pijls-Johannesma M, Lambin P. Design of and technical challenges involved in a framework for multicentric radiotherapy treatment planning studies. Radiother Oncol. 2010 Dec;97(3):567–71.

17. Cheng Q, Roelofs E, Ramaekers BLT, Eekers D, van Soest J, Lustberg T, Hendriks T, Hoebers F, van der Laan HP, Korevaar EW, Dekker A, Langendijk JA, Lambin P. Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness. Radiother Oncol. 2016 Feb;118(2):281–5.

18. Baumert BG, Norton IA, Lomax AJ, Davis JB. Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1314–24.

19. Pijls-Johannesma M, Grutters JPC, Verhaegen F, Lambin P, De Ruysscher D. Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review. Oncologist. 2010;15(1):93–103.

20. Janssen FMFC, Landry G, Cambraia Lopes P, Dedes G, Smeets J, Schaart DR, Parodi K, Verhaegen F. Factors influencing the accuracy of beam range estimation in proton therapy using prompt gamma emission. Phys Med Biol. 2014 Aug 7;59(15):4427–41.

21. Engelsman M, Rietzel E, Kooy HM. Four-dimensional proton treatment planning for lung tumors. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1589–95.

22. Peeters A, Grutters JPC, Pijls-Johannesma M, Reimoser S, De Ruysscher D, Severens JL, Joore MA, Lambin P. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010 Apr;95(1):45–53.

23. Zindler JD, Thomas CR, Hahn SM, Hoffmann AL, Troost EGC, Lambin P. Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription. J Natl Cancer Inst. 2016 Feb;108(2).

24. Lambin P, Zindler J, Vanneste B, van de Voorde L, Jacobs M, Eekers D, Peerlings J, Reymen B, Larue RTHM, Deist TM, de Jong EEC, Even AJG, Berlanga AJ, Roelofs E, Cheng Q, Carvalho S, Leijenaar RTH, Zegers CML, van Limbergen E, Berbee M, van Elmpt W, Oberije C, Houben R, Dekker A, Boersma L, Verhaegen F, Bosmans G, Hoebers F, Smits K, Walsh S. Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncol. 2015;54(9):1289–300.

25. Seravalli E, Robert C, Bauer J, Stichelbaut F, Kurz C, Smeets J, Van Ngoc Ty C, Schaart DR, Buvat I, Parodi K, Verhaegen F. Monte Carlo calculations of positron emitter yields in proton radiotherapy. Phys Med Biol. 2012 Mar 21;57(6):1659–73.

26. Palmans H, Verhaegen F. Monte Carlo study of fluence perturbation effects on cavity dose response in clinical proton beams. Phys Med Biol. 1998 Jan;43(1):65–89.

27. Schmid S, Landry G, Thieke C, Verhaegen F, Ganswindt U, Belka C, Parodi K, Dedes G. Monte Carlo study on the sensitivity of prompt gamma imaging to proton range variations due to interfractional changes in prostate cancer patients. Phys Med Biol. 2015 Nov 18;60(24):9329–47.

28. Wink KCJ, Roelofs E, Solberg T, Lin L, Simone CB, Jakobi A, Richter C, Lambin P, Troost EGC. Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature. Front Oncol. 2014;4:292.

29. Pijls-Johannesma M, Grutters JPC, Lambin P, Ruysscher DD. Particle therapy in lung cancer: where do we stand? Cancer Treat Rev. 2008 May;34(3):259–67.

30. Sheehan M, Timlin C, Peach K, Binik A, Puthenparampil W, Lodge M, Kehoe S, Brada M, Burnet N, Clarke S, Crellin A, Dunn M, Fossati P, Harris S, Hocken M, Hope T, Ives J, Kamada T, London AJ, Miller R, Parker M, Pijls-Johannesma M, Savulescu J, Short S, Skene L, Tsujii H, Tuan J, Weijer C. Position statement on ethics, equipoise and research on charged particle radiation therapy. J Med Ethics. 2014 Aug;40(8):572–5.

31. Lambin P, van Stiphout RGPM, Starmans MHW, Rios-Velazquez E, Nalbantov G, Aerts HJWL, Roelofs E, van Elmpt W, Boutros PC, Granone P, Valentini V, Begg AC, De Ruysscher D, Dekker A. Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol. 2013 Jan;10(1):27–40.

32. Pijls-Johannesma MCG, de Ruysscher DKM, Dekker AL a. J, Lambin P. [Protons and ions in the treatment of cancer; a systematic review of the literature]. Ned Tijdschr Geneeskd. 2006 Nov 4;150(44):2435–41.

33. Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton Therapy in Children – A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. Int J Radiat Oncol Biol. 2016;

34. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: current clinical evidence. J Clin Oncol. 2007 Mar 10;25(8):965–70.

35. Lambin P, Roelofs E, Reymen B, Velazquez ER, Buijsen J, Zegers CML, Carvalho S, Leijenaar RTH, Nalbantov G, Oberije C, Scott Marshall M, Hoebers F, Troost EGC, van Stiphout RGPM, van Elmpt W, van der Weijden T, Boersma L, Valentini V, Dekker A. “Rapid Learning health care in oncology” - an approach towards decision support systems enabling customised radiotherapy’. Radiother Oncol. 2013 Oct;109(1):159–64.

36. Roelofs E, Engelsman M, Rasch C, Persoon L, Qamhiyeh S, de Ruysscher D, Verhaegen F, Pijls-Johannesma M, Lambin P, ROCOCO Consortium. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol. 2012 Jan;7(1):165–76.

37. Verhaegen F, Palmans H. Secondary electron fluence perturbation by high-Z interfaces in clinical proton beams: a Monte Carlo study. Phys Med Biol. 1999 Jan;44(1):167–83.

38. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013 Jun;107(3):267–73.

39. Meldolesi E, van Soest J, Damiani A, Dekker A, Alitto AR, Campitelli M, Dinapoli N, Gatta R, Gambacorta MA, Lanzotti V, Lambin P, Valentini V. Standardized data collection to build prediction models in oncology: a prototype for rectal cancer. Future Oncol. 2016 Jan;12(1):119–36.

40. De Ruysscher D, Belderbos J, Reymen B, van Elmpt W, van Baardwijk A, Wanders R, Hoebers F, Vooijs M, Ollers M, Lambin P. State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clin Lung Cancer. 2013 Mar;14(2):89–95.

41. Ramaekers BLT, Pijls-Johannesma M, Joore MA, van den Ende P, Langendijk JA, Lambin P, Kessels AGH, Grutters JPC. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. Cancer Treat Rev. 2011 May;37(3):185–201.

42. Grutters JPC, Pijls-Johannesma M, Ruysscher DD, Peeters A, Reimoser S, Severens JL, Lambin P, Joore MA. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research. Cancer Treat Rev. 2010 Oct;36(6):468–76.

43. De Ruysscher D, Pijls-Johannesma M, Chang JY, Langendijk JA. The cost of setting up and operating a hadron facility. In regard to Vanderstraeten et al. Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):238.

44. Widder J, van der Schaaf A, Lambin P, Marijnen CAM, Pignol J-P, Rasch CR, Slotman BJ, Verheij M, Langendijk JA. The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine. Int J Radiat Oncol Biol Phys. 2015 Oct 9;

45. Biegun AK, Seravalli E, Lopes PC, Rinaldi I, Pinto M, Oxley DC, Dendooven P, Verhaegen F, Parodi K, Crespo P, Schaart DR. Time-of-flight neutron rejection to improve prompt gamma imaging for proton range verification: a simulation study. Phys Med Biol. 2012 Oct 21;57(20):6429–44.

46. De Ruysscher D, Sterpin E, Haustermans K, Depuydt T. Tumour Movement in Proton Therapy: Solutions and Remaining Questions: A Review. Cancers (Basel). 2015;7(3):1143–53.

47. Palmans H, Seuntjens J, Verhaegen F, Denis JM, Vynckier S, Thierens H. Water calorimetry and ionization chamber dosimetry in an 85-MeV clinical proton beam. Med Phys. 1996 May;23(5):643–50.

48. Palmans H, Seuntjens J, Verhaegen F, Denis JM, Vynckier S, Thierens H. [Water calorimetry measurements in a 85 MeV clinical proton beam]. Bull Cancer Radiother. 1996;83 Suppl:176s – 8s.

49. Grutters JPC, Abrams KR, de Ruysscher D, Pijls-Johannesma M, Peters HJM, Beutner E, Lambin P, Joore MA. When to wait for more evidence? Real options analysis in proton therapy. Oncologist. 2011;16(12):1752–61.